SEARCH RESULTS FOR: "Tag: INCY"
REFINE YOUR SEARCH:
ARTICLES/BLOGS
2019(3)
2018(6)
2017(8)
2016(7)
2015(1)
CATEGORIES
Analyst Downgrades(1)
Analyst Update(3)
Analyst Upgrades(2)
Best and Worst Stocks(2)
Buzz Stocks(5)
Editor's Pick(1)
Expectational Analysis(1)
General(1)
Intraday Option Activity(4)
Midday Market Check(3)
Opening View(1)
Quantitative Analysis(2)
Stock Market News(2)
Stocks On the Move(4)
Technical Analysis(1)
VIX and Volatility(1)

6/17/2019 1:10 PM
Several healthcare stocks are higher today, led by Pfizer (PFE) buyout target Array Biopharma (ARRY). In addition, fellow biotech ArQule, Inc. (NASDAQ:ARQL) is among the best stocks on the Nasdaq t...
4/3/2019 2:21 PM
The shares of Incyte Corporation (NASDAQ:INCY) are down 2.8% to trade at $84.30, after RBC downgraded the biotech name to "sector perform" from "outperform." The analyst in coverage doesn't see any mo...
2/4/2019 10:32 AM
The shares of Incyte Corporation (NADSAQ:INCY) were pointed higher in pre-market trading, after the company's experimental atopic dermatitis treatment met the main goal in two late-stage studies. The...
10/19/2018 2:19 PM
Earlier today, Incyte Corporation (NASDAQ:INCY) reported upbeat results from its mid-stage study of Capmatinib, the company's lung cancer treatment sponsored by Novartis (NOVN). Incyte Corporation sa...
10/12/2018 2:20 PM
Stocks earlier this week were clobbered, turning in their worst day in months. However, many individual stocks have flashed bullish signals in the wake of the bloodbath. If past is precedent, two heal...

Welcome to Schaeffer's Investment Research! We are a privately held provider of stock and options trading recommendations, options education, and market commentary, headquartered in Cincinnati, Ohio. Founded in 1981 by industry pioneer Bernie Schaeffer, we've since become a trusted source of research and analysis for individual investors and major financial media outlets alike.







Partner Center